AcelRx Pharmaceuticals (ACRX)
Add to Watchlists Create an Alert
7.29
+0.89 +13.91%
NASDAQ
May 22, 4:59PM
BATS Real time
Currency in USD
AcelRx Pharmaceuticals Cash from Financing Quarterly:
42.33M for Dec. 31, 2012AcelRx Pharmaceuticals Historical Cash from Financing Quarterly Data
Pro Data Export
Dates:
to
There is no data for the selected date range.
| Data for this Date Range | |
|---|---|
| Dec. 31, 2012 | 42.33M |
| Sept. 30, 2012 | -1.746M |
| June 30, 2012 | 9.091M |
| March 31, 2012 | 0.089M |
| Dec. 31, 2011 | 9.998M |
| Sept. 30, 2011 | 0.146M |
| June 30, 2011 | 5.498M |
| March 31, 2011 | 33.96M |
| Dec. 31, 2010 | -1.22M |
| Sept. 30, 2010 | 6.815M |
| June 30, 2010 | -1.162M |
| March 31, 2010 | -1.068M |
| Sept. 30, 2009 | -1.627M |
About Cash From Financing
An item on a company's cash flow statement. Lists aggregate change in cash position resulting from financing activities. Includes the company's cash inflows and outflows from issuing cash dividends, issuing and selling stock, and adding or changing loans.
Learn More
ACRX Cash from Financing Quarterly Benchmarks
| Companies | |
|---|---|
| Astex Pharmaceuticals | |
| Cyanotech Corporation | -0.019M |
| Intercept Pharmaceuticals |
ACRX Cash from Financing Quarterly Rankings
| Overall |
93rd percentile 502 of 8005 |
| Sector |
94th percentile 40 of 686 in Healthcare |
| Industry |
94th percentile 3 of 55 in Drug Manufacturers - Major |
ACRX Cash from Financing Quarterly Range, Past 5 Years
| Minimum | -1.746M | Sep 2012 |
| Maximum | 42.33M | Dec 2012 |
| Average | 7.778M |
ACRX News
AcelRx Pharma (ACRX) Stock Higher; Sufentanil NanoTab Study Meets Primary Endpoint
Street Insider May 21
Street Insider May 21